VivoSeq
Other

Neuroimaging

0

Pipeline Programs

7

Active Trials

0

Companies Involved

Neuroimaging is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

4/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

26

clinical trials

Completed15 · 58%
Recruiting7 · 27%
Unknown status3 · 12%
Withdrawn1 · 4%

Trial Activity

26 trials

Psychiatric Multi-omics and Neuroimaging Project
Recruiting··N/A·NCT06580860·1,899 enrolled
Remimazolam NeuroImaging
Recruiting··Phase 1·NCT07290205·60 enrolled
Ketamine and Propofol NeuroImaging
Recruiting··Phase 1·NCT07294092·60 enrolled
PET Neuroimaging of [11C]Mirtazapine
Completed·UUniversity of Aarhus·Phase 4·NCT00288782·24 enrolled
Neuroimaging Ancillary Study
Completed·TThomas Jefferson University·N/A·NCT05545527·184 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)